vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and Ranpak Holdings Corp. (PACK). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $93.7M, roughly 1.5× Ranpak Holdings Corp.). On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 2.3%). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 13.7%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
Ranpak Holdings Corp. manufactures machines and paper products used in protective paper-based packing for shipping goods and merchandise for e-commerce and industry, along with automation solutions. The company is based in Concord, Ohio, and has production facilities and offices in Reno, Nevada; Kansas City, Missouri; the Netherlands; Czech Republic; Shanghai and Singapore. The paper packaging material can be used for multiple applications like wrapping, cushioning, void fill and cold chain p...
ADMA vs PACK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $93.7M |
| Net Profit | $49.4M | — |
| Gross Margin | 63.8% | 39.0% |
| Operating Margin | 45.1% | -1.0% |
| Net Margin | 35.5% | — |
| Revenue YoY | 18.4% | 2.3% |
| Net Profit YoY | -55.9% | — |
| EPS (diluted) | $0.20 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | $93.7M | ||
| Q3 25 | $134.2M | $83.6M | ||
| Q2 25 | $122.0M | $77.8M | ||
| Q1 25 | $114.8M | $77.6M | ||
| Q4 24 | $117.5M | $91.6M | ||
| Q3 24 | $119.8M | $78.6M | ||
| Q2 24 | $107.2M | $72.8M | ||
| Q1 24 | $81.9M | $72.5M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $-10.4M | ||
| Q2 25 | $34.2M | $-7.5M | ||
| Q1 25 | $26.9M | $-10.9M | ||
| Q4 24 | $111.9M | — | ||
| Q3 24 | $35.9M | $-8.1M | ||
| Q2 24 | $32.1M | $5.5M | ||
| Q1 24 | $17.8M | $-8.1M |
| Q4 25 | 63.8% | 39.0% | ||
| Q3 25 | 56.3% | 41.1% | ||
| Q2 25 | 55.1% | 37.1% | ||
| Q1 25 | 53.2% | 39.8% | ||
| Q4 24 | 53.9% | 45.2% | ||
| Q3 24 | 49.8% | 43.8% | ||
| Q2 24 | 53.6% | 43.5% | ||
| Q1 24 | 47.8% | 44.6% |
| Q4 25 | 45.1% | -1.0% | ||
| Q3 25 | 38.0% | -6.8% | ||
| Q2 25 | 35.1% | -12.5% | ||
| Q1 25 | 30.4% | -10.3% | ||
| Q4 24 | 32.6% | 1.5% | ||
| Q3 24 | 33.1% | -5.3% | ||
| Q2 24 | 36.6% | -7.1% | ||
| Q1 24 | 26.7% | -6.6% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | -12.4% | ||
| Q2 25 | 28.1% | -9.6% | ||
| Q1 25 | 23.4% | -14.0% | ||
| Q4 24 | 95.2% | — | ||
| Q3 24 | 30.0% | -10.3% | ||
| Q2 24 | 29.9% | 7.6% | ||
| Q1 24 | 21.7% | -11.2% |
| Q4 25 | $0.20 | $-0.11 | ||
| Q3 25 | $0.15 | $-0.12 | ||
| Q2 25 | $0.14 | $-0.09 | ||
| Q1 25 | $0.11 | $-0.13 | ||
| Q4 24 | $0.45 | $-0.13 | ||
| Q3 24 | $0.15 | $-0.10 | ||
| Q2 24 | $0.13 | $0.07 | ||
| Q1 24 | $0.08 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $63.0M |
| Total DebtLower is stronger | $72.1M | $401.9M |
| Stockholders' EquityBook value | $477.3M | $534.9M |
| Total Assets | $624.2M | $1.1B |
| Debt / EquityLower = less leverage | 0.15× | 0.75× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | $63.0M | ||
| Q3 25 | $61.4M | $49.9M | ||
| Q2 25 | $90.3M | $49.2M | ||
| Q1 25 | $71.6M | $65.5M | ||
| Q4 24 | $103.1M | $76.1M | ||
| Q3 24 | $86.7M | $69.5M | ||
| Q2 24 | $88.2M | $65.1M | ||
| Q1 24 | $45.3M | $55.1M |
| Q4 25 | $72.1M | $401.9M | ||
| Q3 25 | $72.4M | $403.1M | ||
| Q2 25 | — | $403.1M | ||
| Q1 25 | — | $405.2M | ||
| Q4 24 | $72.3M | $406.4M | ||
| Q3 24 | — | $403.2M | ||
| Q2 24 | — | $396.1M | ||
| Q1 24 | — | $396.7M |
| Q4 25 | $477.3M | $534.9M | ||
| Q3 25 | $431.2M | $537.8M | ||
| Q2 25 | $398.3M | $539.0M | ||
| Q1 25 | $373.4M | $544.1M | ||
| Q4 24 | $349.0M | $548.1M | ||
| Q3 24 | $231.9M | $564.3M | ||
| Q2 24 | $188.3M | $566.2M | ||
| Q1 24 | $153.7M | $560.0M |
| Q4 25 | $624.2M | $1.1B | ||
| Q3 25 | $568.7M | $1.1B | ||
| Q2 25 | $558.4M | $1.1B | ||
| Q1 25 | $510.6M | $1.1B | ||
| Q4 24 | $488.7M | $1.1B | ||
| Q3 24 | $390.6M | $1.1B | ||
| Q2 24 | $376.4M | $1.1B | ||
| Q1 24 | $350.9M | $1.1B |
| Q4 25 | 0.15× | 0.75× | ||
| Q3 25 | 0.17× | 0.75× | ||
| Q2 25 | — | 0.75× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | 0.21× | 0.74× | ||
| Q3 24 | — | 0.71× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.71× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $19.5M |
| Free Cash FlowOCF − Capex | $34.6M | — |
| FCF MarginFCF / Revenue | 24.8% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | 0.72× | — |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | $19.5M | ||
| Q3 25 | $13.3M | $8.5M | ||
| Q2 25 | $21.1M | $-3.6M | ||
| Q1 25 | $-19.7M | $-1.3M | ||
| Q4 24 | $50.2M | $6.5M | ||
| Q3 24 | $25.0M | $10.1M | ||
| Q2 24 | $45.6M | $19.6M | ||
| Q1 24 | $-2.2M | $5.2M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | $18.7M | — | ||
| Q1 25 | $-24.4M | — | ||
| Q4 24 | $47.5M | — | ||
| Q3 24 | $24.0M | — | ||
| Q2 24 | $43.6M | — | ||
| Q1 24 | $-4.6M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | — | ||
| Q2 25 | 15.3% | — | ||
| Q1 25 | -21.2% | — | ||
| Q4 24 | 40.4% | — | ||
| Q3 24 | 20.0% | — | ||
| Q2 24 | 40.7% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 4.1% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.9% | — | ||
| Q2 24 | 1.9% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | 3.56× | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
PACK
| Other | $47.9M | 51% |
| Europe And Asia Segment | $45.8M | 49% |
